cyrilzakka/clinical-trials huggingface dataset:
A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).


Eligibility Criteria:
Inclusion Criteria:

* The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis by satisfying at least four of the seven criteria.
* The patient must have active disease at both Screening and predose on Day 1 of Period 1.
* Patient must have had an inadequate response to at least one disease-modifying antirheumatic drug (DMARD), non-biologic or biologic, due to ineffectiveness or intolerance.

Exclusion Criteria:

* Pregnant or lactating women
* Serious medical conditions that would make treatment with CP-690,550 potentially unsafe.
* A patient who has a history of asthma, multiple allergies or severe allergy (eg, anaphylaxis) to any substance. In particular, a history of allergy to iodine, povidone-iodine, iohexol or other iodinated contrast media.
Cognitive Training for Attention Deficit Hyperactivity Disorder and Developmental Delays

To explore whether children with Attention Deficit Hyperactivity Disorder and developmental delays who receive cognitive training and conventional rehabilitation can improve executive function more than traditional rehabilitation alone. A magnetoencephalographic examination will be arranged to explore how brain network activation works.

Research method: 20 preschool children with Attention Deficit Hyperactivity Disorder and developmental delays under rehabilitation therapy will be collected. They will be randomly assigned to the experimental group (receiving rehabilitation therapy and three times per week for 15 minutes, a total of 12 weeks of interactive cognitive training) and the control group (receiving rehabilitation therapy only). Therapeutic effects will be evaluated.

Research method: 20 preschool children with Attention Deficit Hyperactivity Disorder and developmental delays under rehabilitation therapy will be collected. They will be randomly assigned to the experimental group (receiving rehabilitation therapy and three times per week for 15 minutes, a total of 12 weeks of interactive cognitive training) and the control group (receiving rehabilitation therapy only). Therapeutic effects will be evaluated, including Sensory Profile, Swanson, Nolan and Pelham version IV, Conners Kiddie Continuous Performance test, Chinese Childhood Executive Functioning Inventory, and Chinese version of Wechsler Intelligence Scale for Children-IV; and physical health conditions, including Pediatric Daily Occupation Scale, Pediatric Outcome Data Collection Instrument (PODCI), Child Health Questionnaire- Parent Form, Pediatric Quality of Life Inventory (PedsQL)will be evaluated by an investigator who is blinded to the group's allocation at before treatment and after 12 weeks of treatment. All participants will be investigated by magnetoencephalography (MEG) to identify the brain network connectivity while performing different tasks before and after 12 weeks of treatment. Brain Magnetic Resonance Imaging will be performed for brain mapping.

Possible results: The study will shed light on therapeutic effects and brain network connectivity by cognitive training for preschool children with Attention Deficit Hyperactivity Disorder and developmental delays.

Eligibility Criteria:
Inclusion Criteria:

* preschool children with Attention Deficit Hyperactivity Disorder and developmental delays under regular rehabilitation programs intelligence quotient 70 or greater

Exclusion Criteria:

* age less than 4 or greater than 6 metal in teeth intelligence quotient less than 70
Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia

The study will compare the analgesic efficacy of transversus abdominis plane block and wound infiltration in parturients undergoing cesarean delivery under spinal anesthesia.

This randomized, controlled, double-blind study will be conducted on ASA physical status II parturients with full-term singleton pregnancy undergoing elective cesarean delivery under spinal anesthesia. Patients will receive either ultrasound-guided transversus abdominis plane block or wound infiltration at the end of surgery. After delivery, all patients will receive standard analgesia (intravenous ketorolac and oral paracetamol) and patient-controlled analgesia with intravenous fentanyl. Total fentanyl consumption at 24 h, pain scores at 2, 4, 6, 12, and 24 h, side effects, and patient satisfaction will be compared between the 2 groups.

Eligibility Criteria:
Inclusion Criteria:

1. American Society of Anesthesiologists physical status II
2. Full-term singleton pregnancy

Exclusion Criteria:

1. Age \<19 or \> 40 years
2. Height \<150 cm
3. Weight \<60 kg
4. Body mass index ≥40 kg/m2
5. Contraindications to spinal anesthesia (patient refusal, increased intracranial tension, coagulopathy, uncorrected hypovolemia)
6. Hypersensitivity to any of the drugs used in the study
7. Significant cardiovascular, renal, or hepatic disease
8. Known fetal abnormalities
9. Emergency situations
Trial Comparing Treatment With SInergy™ System to Conservative Treatment for Chronic Sacroiliac Joint Pain

The purpose of this study is to evaluate the effectiveness of cooled radiofrequency denervation of the sacroiliac region using the SInergy System compared to conservative treatment in the treatment of sacroiliac joint pain.


Eligibility Criteria:
Inclusion Criteria:

* Predominantly axial pain below the L5 vertebrae
* \>75% pain relief from 2 separate lateral branch blocks done on different days (followed by return to baseline pain)
* Chronic axial pain lasting for longer than six months: 3 day average VAS between 4 and 8.
* Age greater than 18 years.
* Failed to achieve adequate improvement with comprehensive non-operative treatments, including but not limited to: activity alteration, non-steroidal anti-inflammatory, physical and/or manual therapy, and fluoroscopically guided steroid injections in and around the area of pathology.
* All other possible sources of low back pain have been ruled out, including but not limited to: the intervertebral discs, bone fracture, the zygapophyseal joints, the hip joint, symptomatic spondylolisthesis, tumor and other regional soft tissue structures (this is done by physical exam, medical history, and MRI/CT/X-ray as required)

Exclusion Criteria:

* Beck Depression Score \>20 or irreversible psychological barriers to recovery
* Spinal pathology that may impede recovery such as spina bifida occulta, spondylolisthesis at L5/S1, or scoliosis.
* Moderate or severe foraminal or central canal stenosis
* Systemic infection or localized infection at anticipated introducer entry site.
* Concomitant cervical or thoracic pain greater than 2/10 on a VAS
* Uncontrolled or acute illness
* Chronic severe conditions such as rheumatoid/inflammatory arthritis
* Pregnancy
* Active radicular pain
* Immunosuppression (eg. AIDS, cancer, diabetes, surgery \<3 months ago)
* Worker's compensation, injury litigation, or disability remuneration
* Allergy to injectants or medications used in procedure
* High narcotics use (\>30 mg hydrocodone or equivalent)
* Patients who smoke. Termination for at least 6 months and no smoking during follow up period are acceptable with caution.
* Body Mass Index greater than 29.9 (obese).
* Subject unwilling to consent to the study
NGAL and Hepcidin Levels in Hemodialysis Patients in Assiut University Hospital

To assess the pattern of NGAL and Hepicidin in relation to anemia in End Stage Renal Disease Patients on regular hemodialysis in Assiut University Hospital and study the relation between both NGAL and Hepicidin.

Patients with chronic kidney disease have a chronic inflammatory state, due to many factors e.g. enhancedincidence of infections, the uremic milieu, elevated levels of proinflammatory cytokines, frequent presence of widespread arteriosclerosis, etc. Iron metabolism is disturbedin chronic inflammatory diseases.AlteredNGAL levels in hemodialysis patients was probablydue to the fact that this protein was involved in ironmetabolism and suggested that NGAL might be anew tool in the assessment of iron deficiency.Another study found in multipleregression analysis that; residual renal function, hepcidin,creatinine and hsCRP were predictors of serum NGAL inhemodialyzed patients. They concluded that NGAL is highly induced in dialyzed patients and could reflect both kidney function and iron metabolism.Several studies suggested that hepcidin plays a role as anegative regulator of intestinal iron absorption and ironrelease from macrophages. Hepcidin controls intestinal ironabsorption by regulating ferroportin expression on thebasolateral membrane of enterocytes .Hepicidin is also an acute phase reactant.Both NGAL and hepcidin are elevated inchronic kidney disease,not only through ironmetabolism, but both are also associated with inflammationand may be related to anemia. Possible relationship between NGAL and hepicidin is still under study.

Eligibility Criteria:
Inclusion Criteria:

For group 1:

1. Adults \> 18 years.
2. Age and sex matched.
3. No active infection or inflammation.

For group 2:

1. Adults \> 18 years.
2. ESRD patients on regular hemodialysis.
3. Hgb \< 11g/dl.
4. No apparent infection or inflammation.

For group 3:

1. Adults \> 18 years.
2. ESRD patients on regular hemodialysis.
3. Hgb ≥ 11g/dl.
4. No apparent infection or inflammation.

Exclusion Criteria:

1. Children and those \>60 Years.
2. Pregnant female.
3. Patients with severe infection or with other immune system diseases.
Postoperative Outcomes of Covid-19 Patients Who Were Hospitalized in a Training and Research Hospital, Who Were Operated on Electively

The Covid-19 infection has led to global health crisis. As the number of patients recovering from Covid-19 infection increases, it is necessary to create an understanding of the health problems that concern them. Reports of persistent and long-lasting effects are increasing after Covid-19 infection .

Data on postoperative outcomes in the patient population with Covid-19 infection are limited. In more than half of these patients, pulmonary complications and mortality are seen between 19-24%. Covid-19 infection positivity has been shown as an independent risk factor for surgical mortality. In this study, we aimed to examine the results of patients who were hospitalized and operated electively after they has Covid-19. Among the patients who were hospitalized and followed up in our hospital due to Covid-19 infection between July 2020 and July 2021, those over the age 18 and opereted on electively will be included in the study. By accessing the hospital records, patients Covid-19 treatment records, length of hospital stay, intensive care follow-up, processes, pulmonary support conditions, lung involvement, time until the operation, operation type, operation time, ASA classification, anesthesia type, post-operative follow-up processes, post-operation intensive care needs, time to discharge and mortality will be examined. After the data of of the patients were recorded using SPSS19 program, statistical analysis will be performed using the arithmetic mean, median, standart deviation and Chi-square test, which are among the measures of distribution and prevalence.

Eligibility Criteria:
Inclusion Criteria:

* over 18 years old
* those who elective surgery
* patients who have had Covid-19

Exclusion Criteria:

* emergency surgery
* under 18 years old
Family Meeting Study for End Stage Renal Disease

A randomized clinical trial for patients with end stage renal disease in which a family consultation condition is compared against a treatment as usual control condition on the hospital readmissions after 1 month as the primary outcome variable.

Patients hospitalized at Henry For Hospital who have end stage renal disease will complete baseline questionnaires and be randomized into the experimental or control condition. Patients randomized into the experimental condition will have a single family consultation session before the patient is discharged. A trained, master's level therapist will conduct the family consultation, which will use education, motivational interviewing, and other techniques to help the family engage and support the patient's health needs. Patients in both the experimental and control conditions will complete follow up questionnaires 1 month after discharge. Investigators will conduct chart reviews of outcome data, including readmissions, at 1, 3, and 6 months post-discharge.

Eligibility Criteria:
Inclusion Criteria:

* Hospitalized in inpatient Nephrology Unit at Henry Ford Hospital
* Has end-stage renal disease
* Willing and able to contact support person / family member about participating in the study

Exclusion Criteria:

* Persistent Delirium
* Non-English speaking
Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer

Surgical site infections are an important health indicator for hospitals and a significant medico-economic issue.

The aim of the study is to assess the impact of chlorhexidine mouthwash performed before surgery on the bacterial colonization of the pharyngeal mucosa.

The main objective is to reduce the number of patients with significant pathogenic bacterial colonization for pharyngeal mucosa at the end of the surgery. Oral flora is the same as the pharyngeal flora, so this suggests that the action of the oral mouthwash may also act in pharyngeal mucosa by buccopharyngeal communication.

Patients will be randomized into two groups :

* preoperative oral preparation with sodium chloride (NaCl) 0.9% (control group)
* preoperative oral preparation with chlorhexidine (experimental group)

A quantitative and qualitative analysis will be performed from samples collected during the surgery : before mouthwash (T0), after mouthwash (T1), before intubation in the operating room (T2), after intubation (T3), before incision (T4) and just before the end of the intervention on the mucosal scar (T5)

Eligibility Criteria:
Inclusion Criteria:

* Histological evidence of cancer regardless of histological type
* Surgical treatment requiring mucosal effraction regardless of the surgical approach;
* Patient over 18 years old;
* Oral cancer, oropharyngeal cancer, hypopharyngeal cancer or laryngeal cancer;
* Written and informed patient consent

Exclusion Criteria:

* Concomitant Vascular Interventions;
* Interventional radiology;
* Needing of second surgery at a same location during the 30 postoperative days);
* Cancer of the paranasal sinus, nasal cavity, skull base, salivary glands, skin,
* Neck dissection without mucosal effraction
* Thyroid or parathyroid surgery
* Size tumor forbidden tumor surgery
* Allergy to any tested product;
* Concurrent infection the day before or day of surgery
* Protected adults (guardianship) and persons deprived of liberty
Evaluation of the Efficacy and Safety of Herbal Medicine for Treating Work-related Chronic Low Back Pain

The Purpose of this trial is to investigate the efficacy and safety of Sogyeonghwalhyeol-tang(SGHH) on Korean Patients With Work Related Chronic Low Back Pain

Investigating the efficacy and safety of Sogyeonghwalhyeol-tang(SGHH) on Korean Patients With Work-related Chronic Low Back Pain

Eligibility Criteria:
Inclusion Criteria:

* Inpatients with chief complaint of low back pain in oriental rehabilitation medical center
* Age 19 - 65
* Workplace Vulnerable populations(hospital workers, office worker, blue collar workers, transit workers)
* Patients must include all of the following symptoms:

  * Those who have 4 \~7 cm of VAS pain score;
  * Those who has classified as 'at risk non-complier' or 'pain complaints' by KOSHA questionnaire
* Ability to have normal communication
* Ability to give informed consent

Exclusion Criteria:

1. Patients with pain duration of 3 months or less
2. Patients with progressive neurologic deficit or severe neurologic symptoms by SLR test
3. Patients diagnosed with serious pathology(s) which may cause low back pain (e.g. spinal metastasis of tumor(s), acute fracture, etc)
4. Patients with spondylolisthesis or spondylolysis(diagnosed with grade II or higher level)
5. Patients currently taking steroids, immunosuppressants, medicine for mental illness or other medication(s) that may interfere with study results
6. Patients with history of spinal surgery
7. Patients with more severe pain than pain caused by low back pain
8. Those who do not (cannot) abide by treatment and follow up due to the mental illness such as behavior disorder, depression, anxiety neurosis etc.
9. Patients with history of Medical Malpractice Case
10. Patients with treatment history of low back pain within 1 month either KM or WM
11. Patients participating in other clinical studies within 3 months
12. Pregnant patients or patients with plans of pregnancy or lactating patients
13. Patients disagree to sign the informed consent form
14. Patients deemed unsuitable for participating the trial by the researchers
Effect of Giving Reduced Fluid in Children After Trauma

This study is designed to help decide how much intravenous (IV) fluid should be given to pediatric trauma patients. No standard currently exists for managing fluids in critically ill pediatric trauma patients, and many fluid strategies are now in practice. For decades, trauma patients got high volumes of IV fluid. Recent studies in adults show that patients actually do better by giving less fluid. The investigators do not know if this is true in children and this study is designed to answer that question and provide guidelines for IV fluid management in children after trauma.

Aggressive fluid resuscitation has been the cornerstone of early post-operative and trauma management for decades. However, recent prospective adult studies have challenged this practice, linking high volume crystalloid resuscitation to increased mortality, cardiopulmonary, gastrointestinal and hematologic complications. A retrospective study the investigators recently performed at their quaternary-care children's hospital echoed these results. High quality prospective data is necessary to determine best practice guidelines in our pediatric surgery and trauma patients.

Currently, no standard exists to guide management of crystalloid fluid administration in trauma patients. Both liberal and restricted strategies are in use, dependent on physician discretion. The investigators propose the first randomized controlled trial (RCT) comparing a liberal to a restricted fluid management strategy in critically ill pediatric trauma patients. The objective of this comparative effectiveness study is to conduct a multicenter (around 10 sites) randomized controlled trial (RCT) to determine whether liberal or restricted fluid administration leads to better outcomes in these patients.

Eligibility Criteria:
Inclusion Criteria:

* Trauma patients older than 6 months and younger than 15 years admitted to the pediatric intensive care unit (PICU)
* Patients admitted to the PICU directly from the Emergency Department (ED)
* Patients admitted to the PICU from the operating room (OR)
* Patients transferred to PICU from outside facility ED (need to have been in ED 12 hours or less)

Exclusion Criteria:

* Patients transferred to PICU from outside PICU or inpatient floor
* Patients transferred to PICU from outside facility ED if \>12 hours
* Patients expected to be discharged from the PICU within 24 hours
* Patient with congenital heart disease as defined by a congenital cardiac defect requiring surgery or medication
* Patient with diagnosis of chronic cardiac condition (e.g. hypertension, cardiac arrhythmia)
* Patients with chronic kidney disease as defined by an abnormality of kidney structure or function, present for more than 3 months, with implications to health
* Post-operative transplant, cardiac, and neurosurgical patients
* Patients with traumatic brain injury
* Patients with any disease that may affect baseline blood pressure and heart rate (endocrine disorders, certain genetic disorders, mitochondrial diseases)
* Hypotension requiring vasopressor therapy
* If massive transfusion protocol initiated
A Dual Energy Catheter (PFA and RFA) and a PFA Catheter for the Treatment of PeAF

The goal of this clinical trial is to treatment of patients with persistent atrial fibrillation with PFA/RFA. 10 patients will be treated by PFA/RFA catheter or PFA catheter only.

Participants will followed 1、3 month after catheter ablation


Eligibility Criteria:
Inclusion Criteria:

1. Aged 18-75 years old;
2. Documented symptomatic persistent atrial fibrillation, defined as persistent atrial fibrillation lasting more than 7 days and less than 1 year；
3. Ineffective or intolerable after treatment with at least one Class I or Class III antiarrhythmic drug;
4. Fully understand the treatment protocol and voluntarily sign the informed consent form and be willing to undergo the tests, procedures and follow-ups required by the protocol.

Exclusion Criteria:

1. Patients who have undergone left atrial surgery
2. Left atrial thrombosis
3. Patients with combined atrial tachycardia and atypical atrial flutter
4. Patients of childbearing age who are unable to use effective contraception during the 3-month period following enrollment
5. Anterior and posterior left atrial diameter ≥ 55mm
6. Left ventricular ejection fraction (LVEF) ≤ 40%
7. Previous atrial septal repair or atrial mucinous tumor
8. Active implants (e.g. pacemakers, ICDs, etc.) in the body
9. NYHA class III-IV cardiac function
10. Clear cerebrovascular disease within the last 6 months (including cerebral hemorrhage, stroke, transient ischemic attack)
11. Cardiovascular events within the last 3 months (including acute myocardial infarction, coronary intervention or heart bypass surgery, prosthetic valve replacement or repair, atrial or ventriculotomy)
12. Those with acute or severe systemic infections
13. Patients with severe liver or kidney disease, malignant tumors or end-stage disease that, in the opinion of the investigator, may interfere with the treatment, evaluation and compliance of this trial
14. Patients with significant bleeding tendency, hypercoagulable state and severe hematologic disorders
15. Patients who have participated or are participating in other clinical trials within 3 months prior to enrollment
16. Patients who have other conditions that the investigator considers inappropriate for participation in this trial.
In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule

The investigators developed \[68Ga\]-labelling Anti-EGFR Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-ECD expression status.

The goals of investigators are to evaluate the use of \[68Ga\]-labelling Anti-EGFR Affibody Molecule as a novel PET/CT radiotracer to monitor EGFR-ECD expression status and classify EGFR-ECD benefit NSCLC patients. The investigators want to evaluated the use of \[68Ga\]-labelling Anti-EGFR Affibody Molecule in lung cancer imaging in adult NSCLC patients with different EGFR-ECD expression status of primary and metastatic cancers.

Eligibility Criteria:
Inclusion Criteria:

* Advanced NSCLC
* 18 years or older
* A life expectancy of at least 12 weeks
* Presence of a malignant lesion within the chest of at least 0.5 cm diameter as measured by computed tomography (CT)
* Written informed consent

Exclusion Criteria:

* Claustrophobia
* Pregnancy
* Metal implants in the thorax